The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Despite the buzz around GLP-1 medications like Wegovy and Zepbound, obesity rates in the U.S. are projected to hit nearly 50% by 2030, per a New England Journal of Medicine study. Severe obesity (BMI 40+) continues to rise, highlighting disparities in food access and demographics. UVA expert Dr. Cate Varney breaks down what this means for public health and patients.
Kelly Osbourne stunned fans with her ultra-thin look at the 2026 Grammy Awards, reigniting 'Ozempic face' rumors despite her firm denial of using the drug. After losing 85 pounds through cutting sugar and carbs following gestational diabetes, public skepticism grows amid her skeletal appearance. Discover the story behind the transformation and medical insights on rapid weight loss effects.
Bollywood veteran Farida Jalal couldn't resist a cheeky remark about producer Sajid Nadiadwala's impressive 27-inch waistline, fueling ongoing rumors that Ozempic fueled his dramatic body transformation. As his film O Romeo hits theaters, the chatter highlights growing celebrity interest in GLP-1 medications for weight loss. Explore the story and science behind it.
A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.
Semax, a synthetic heptapeptide derived from ACTH research, is capturing interest for its neuroactive properties without endocrine effects. Ongoing studies highlight its roles in neuroplasticity, stress resilience, and cognitive function. This guide delves into the science behind its multifaceted research potential.
GLP-1 weight loss drugs such as Wegovy and Zepbound have revolutionized obesity care, leading to up to 20% body weight reduction over 72 weeks. These therapies challenge old views of obesity as mere lifestyle failure, highlighting brain hunger centers, genetics, and hormones. From chronic disease recognition to equitable access, here's how they've reshaped treatment.
Emerging research is spotlighting a potential link between popular GLP-1 medications like Ozempic and Wegovy and hair loss conditions such as telogen effluvium and androgenetic alopecia. A study of nearly 550,000 patients found a significant association after 12 months of use, even after adjusting for key factors. While benefits for diabetes and weight loss remain strong, awareness and monitoring are crucial.
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
